AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

• Deep Vein Thrombosis
• Pulmonary Embolism

• Drug: Apixaban
  
  10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
• Drug: Unfractionated Heparin (UFH)
  
  Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ? 1.5 for 5 days or more
• Drug: Warfarin
  
  Dosing for 24 weeks to target INR range between 1.5-2.5

• Experimental: Apixaban
  
  Intervention: Drug: Apixaban
• Active Comparator: UFH/Warfarin
  
  Interventions:
  

  • Drug: Unfractionated Heparin (UFH)
  • Drug: Warfarin

Inclusion Criteria:

• Acute symptomatic proximal DVT with evidence of proximal thrombosis
• Acute symptomatic PE with evidence of thrombosis in segmental or more proximal branches

Exclusion Criteria:

• Active bleeding or high risk for bleeding contraindicating treatment with UFH and a VKA.
• Uncontrolled hypertension: systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg
• Subjects requiring dual anti-platelet therapy